ETFs Monte Rosa Therapeutics, Inc.

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2026-10-30 pm EDT			5-day change	1st Jan Change
10.76 ^USD	-1.01%		-0.74%	-31.38%

Oct. 28	Monte Rosa Therapeutics Announces Second Phase 2 Clinical Study Initiation for VAV1-Directed Molecular Glue Degrader MRT-6160	CI
Oct. 12	UBS Adjusts Price Target on Monte Rosa Therapeutics to $19 From $17, Maintains Buy Rating	MT

ETFs positioned on Monte Rosa Therapeutics, Inc.

Name	YTD change	Weight	AuM
VIRTUS LIFESCI BIOTECH CLINICAL TRIALS ETF - USD	+11.64%	0.93%	50 M€
INVESCO DWA HEALTHCARE MOMENTUM ETF - USD	+20.28%	0.76%	258 M€
INVESCO DWA SMALLCAP MOMENTUM ETF - USD	+8.13%	0.44%	462 M€
EA BRIDGEWAY OMNI SMALL-CAP VALUE ETF - USD	+24.33%	0.27%	2,474 M€
GLOBAL X S&P BIOTECH ETF - AUD	+22.92%	0.27%	35 M€
STATE STREET SPDR S&P BIOTECH ETF - USD	+27.93%	0.25%	10,676 M€
AVANTIS U.S. SMALL CAP VALUE ETF - USD	+21.03%	0.16%	31,034 M€
ISHARES MICRO-CAP ETF - USD	+12.99%	0.16%	1,518 M€
AVANTIS U.S. SMALL CAP EQUITY ETF - USD	+21.35%	0.09%	3,154 M€
ISHARES NASDAQ US BIOTECHNOLOGY UCITS ETF (D) - USD	+28.57%	0.09%	78 M€
ISHARES NASDAQ US BIOTECHNOLOGY UCITS ETF - USD	+28.50%	0.09%	1,079 M€
INVESCO NASDAQ BIOTECHNOLOGY ETF - USD	+27.38%	0.08%	81 M€
ISHARES BIOTECHNOLOGY ETF - USD	+28.94%	0.08%	9,953 M€
INNOVATOR U.S. SMALL CAP MANAGED FLOOR ETF - USD	+11.91%	0.06%	94 M€
VANGUARD RUSSELL 2000 VALUE ETF - USD	+18.10%	0.05%	1,392 M€
INVESCO RAFI US 1500 SMALL-MID ETF - USD	+15.71%	0.05%	2,894 M€
MCELHENNY SHEFFIELD MANAGED RISK ETF - USD	+1.78%	0.05%	186 M€
GOLDMAN SACHS ACTIVEBETA U.S. SMALL CAP EQUITY ETF - USD	+15.47%	0.03%	1,095 M€
GLOBAL X RUSSELL 2000 ETF (AU) - AUD	+9.11%	0.03%	18 M€
SCHWAB U.S. SMALL-CAP ETF - USD	+15.84%	0.03%	23,313 M€
ISHARES U.S. SMALL CAP INDEX ETF (CAD-HEDGED) - CAD	+11.85%	0.03%	520 M€
CI INVESCO RAFI GLOBAL SMALL-MID ETF - CAD	-.--%	0.03%	19 M€
ISHARES RUSSELL 2000 ETF - USD	+13.47%	0.03%	82,179 M€
GLOBAL X RUSSELL 2000 COVERED CALL & GROWTH ETF - USD	+5.37%	0.03%	9 M€
GLOBAL X RUSSELL 2000 ETF - USD	+13.08%	0.03%	1,540 M€
XTRACKERS RUSSELL 2000 UCITS ETF 1C - USD	+17.84%	0.02%	3,050 M€
AVANTIS RESPONSIBLE U.S. EQUITY ETF - USD	+13.84%	0.02%	489 M€
ISHARES RUSSELL 2000 VALUE ETF - USD	+18.42%	0.01%	14,676 M€
GLOBAL X RUSSELL 2000 COVERED CALL ETF - USD	+0.13%	0.01%	1,395 M€
VANGUARD HEALTH CARE ETF - USD	+18.93%	0.01%	19,074 M€
STATE STREET SPDR RUSSELL 2000 U.S. SMALL CAP UCITS ETF - USD	+13.67%	0.01%	5,739 M€
UNLIMITED HFEQ EQUITY LONG/SHORT ETF - USD	+8.98%	0.01%	19 M€
VANGUARD MSCI INTERNATIONAL SMALL COMPANIES INDEX ETF - AUD	-0.20%	0.01%	675 M€
CI INVESCO RAFI GLOBAL SMALL-MID ETF - USD	+10.08%	0%	0 M€
CI INVESCO RAFI GLOBAL SMALL-MID ETF - CAD HEDGED	-.--%	0%	3 M€
LEUTHOLD CORE ETF - USD	+6.04%	0%	68 M€

1 2 3

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the bodyâ€™s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Employees

173

Sector

Biotechnology & Medical Research

More about the company